CA counties sue makers of painkillers

Share this article:

Two California counties have adopted a new strategy to confront prescription painkiller abuse: a lawsuit. The LA Times reports that Orange and Santa Clara counties have filed a lawsuit against a list of drugmakers that includes Purdue Pharma, Johnson & Johnson subsidiary Janssen Pharmaceuticals, and Endo Health Solutions, among others.

LAT says the text of the lawsuit is “reminiscent of the legal attack against the tobacco industry,” and accuses the drugmakers of “manipulating doctors into believing the benefits of narcotic painkillers outweighed the risks.”

Orange County District Attorney Tony Rackauckas told the LAT that the goal is “to stop the lies about what these drugs do.”

The lawsuit alleges that drugmakers use deceptive marketing practices much like the tobacco industry, such as creating patient advocacy organizations to promote painkillers and write treatment guidelines. These allegations may sound familiar: ProPublica and the Washington Post reported in 2012 that the American Pain Foundation, which received 90% of its funding from drug and device manufacturers, closed up shop, but not before issuing a series of guidelines ProPublica noted downplayed risks associated with opioid medications and exaggerating their benefits.

"These groups, these pain organizations…helped usher in an epidemic that's killed 100,000 people by promoting aggressive use of opioids,” Dr. Andrew Kolodny, chairman of psychiatry at Maimonides Medical Center in Brooklyn, NY, and president of Physicians for Responsible Opioid Prescribing, told ProPublica at the time.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.